AIM: To investigate the outcome of patients with hepatitis C virus (HCV) infection undergoing liver retransplantation. METHODS: Using the UK National Registry, patients undergoing liver transplantation for HCV-related liver disease were identified. Data on patient and graft characteristics, as well as transplant and graft survival were collected to determine the outcome of HCV patients undergoing retransplantation and in order to identify factors associated with transplant survival. RESULTS: Between March 1994 and December 2007, 944 adult patients were transplanted for HCV-related liver disease. At the end of follow-up, 617 of these patients were alive. In total, 194 (21%) patients had first graft failure and of these, 80 underwent liver retransplantation, including 34 patients where the first graft failed due to recurrent disease. For those transplanted for HCV-related disease, the 5-year graft survival in those retransplanted for recurrent HCV was 45% [95% confidence interval (CI): 24%-64%] compared with 80% (95% CI: 62%-90%) for those retransplanted for other indications (P = 0.01 log-rank test); the 5-year transplant survival after retransplantation was 43% (95% CI: 23%-62%) and 46% (95% CI: 31%-60%), respectively (P = 0.8, log-rank test). In univariate analysis of all patients retransplanted, no factor analyzed was significantly associated with transplant survival. CONCLUSION: Outcomes for retransplantation in patients with HCV infection approach agreed criteria for minimum transplant benefit. These data support selective liver retransplantation in patients with HCV infection.
AIM: To investigate the outcome of patients with hepatitis C virus (HCV) infection undergoing liver retransplantation. METHODS: Using the UK National Registry, patients undergoing liver transplantation for HCV-related liver disease were identified. Data on patient and graft characteristics, as well as transplant and graft survival were collected to determine the outcome of HCV patients undergoing retransplantation and in order to identify factors associated with transplant survival. RESULTS: Between March 1994 and December 2007, 944 adult patients were transplanted for HCV-related liver disease. At the end of follow-up, 617 of these patients were alive. In total, 194 (21%) patients had first graft failure and of these, 80 underwent liver retransplantation, including 34 patients where the first graft failed due to recurrent disease. For those transplanted for HCV-related disease, the 5-year graft survival in those retransplanted for recurrent HCV was 45% [95% confidence interval (CI): 24%-64%] compared with 80% (95% CI: 62%-90%) for those retransplanted for other indications (P = 0.01 log-rank test); the 5-year transplant survival after retransplantation was 43% (95% CI: 23%-62%) and 46% (95% CI: 31%-60%), respectively (P = 0.8, log-rank test). In univariate analysis of all patients retransplanted, no factor analyzed was significantly associated with transplant survival. CONCLUSION: Outcomes for retransplantation in patients with HCV infection approach agreed criteria for minimum transplant benefit. These data support selective liver retransplantation in patients with HCV infection.
Authors: R M Ghobrial; R Steadman; J Gornbein; C Lassman; C D Holt; P Chen; D G Farmer; H Yersiz; N Danino; E Collisson; A Baquarizo; S S Han; S Saab; L I Goldstein; J A Donovan; K Esrason; R W Busuttil Journal: Ann Surg Date: 2001-09 Impact factor: 12.969
Authors: M Berenguer; M Prieto; J M Rayón; J Mora; M Pastor; V Ortiz; D Carrasco; F San Juan; M D Burgueño; J Mir; J Berenguer Journal: Hepatology Date: 2000-10 Impact factor: 17.425
Authors: Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Massimo Del Gaudio; Matteo Cescon; Giovanni Varotti; Giovanni Ramacciato; Gaetano Vetrone; Matteo Zanello; Antonio Daniele Pinna Journal: Liver Transpl Date: 2006-07 Impact factor: 5.799
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Ian A Rowe; Kerry Webb; Bridget K Gunson; Naimish Mehta; Sayeed Haque; James Neuberger Journal: Transpl Int Date: 2008-01-21 Impact factor: 3.782
Authors: T Bizollon; S N S Ahmed; S Radenne; M Chevallier; P Chevallier; P Parvaz; S Guichard; C Ducerf; J Baulieux; F Zoulim; C Trepo Journal: Gut Date: 2003-02 Impact factor: 23.059
Authors: Angela L Rasmussen; Nicolas Tchitchek; Nathan J Susnow; Alexei L Krasnoselsky; Deborah L Diamond; Matthew M Yeh; Sean C Proll; Marcus J Korth; Kathie-Anne Walters; Sharon Lederer; Anne M Larson; Robert L Carithers; Arndt Benecke; Michael G Katze Journal: Hepatology Date: 2012-06-05 Impact factor: 17.425
Authors: Garrick K Wilson; Claire L Brimacombe; Ian A Rowe; Gary M Reynolds; Nicola F Fletcher; Zania Stamataki; Ricky H Bhogal; Maria L Simões; Margaret Ashcroft; Simon C Afford; Ragai R Mitry; Anil Dhawan; Christopher J Mee; Stefan G Hübscher; Peter Balfe; Jane A McKeating Journal: J Hepatol Date: 2011-12-16 Impact factor: 25.083